Revenue during the quarter grew 6.39 percent to $81.36 million from $76.47 million in the previous year period. Gross margin for the quarter expanded 480 basis points over the previous year period to 48.87 percent. Total expenses were 85.34 percent of quarterly revenues, up from 76.89 percent for the same period last year. That has resulted in a contraction of 845 basis points in operating margin to 14.66 percent.

Operating income for the quarter was $11.93 million, compared with $17.67 million in the previous year period.

However, the adjusted operating income for the quarter stood at $16.34 million compared to $11.84 million in the prior year period. At the same time, adjusted operating margin improved 460 basis points in the quarter to 20.09 percent from 15.49 percent in the last year period.

"2017 is off to a strong start," commented Mary Anne Heino, President and CEO. "We continue to drive volume with higher margin products. Growth in DEFINITY sales once again drove our over-performance. Our nuclear portfolio continues to deliver, and our collaboration agreement with GE Healthcare for flurpiridaz F 18 is now in place. The additional liquidity provided by our debt refinancing allows consideration of investment opportunities for future growth."

 For fiscal year 2017, Lantheus Holdings forecasts revenue to be in the range of $313 million to $318 million. For the second-quarter, Lantheus Holdings forecasts revenue to be in the range of $79 million to $82 million.